Annexin Q2: Positioned to advance: DR study and BD efforts - Redeye

Redeye comments on Annexin’s Q2 report and recent events in the company. Following the Q1 report, we implemented several updates to our model. With the Q2 figures now incorporated, only minor housekeeping adjustments have been made. The company is expected to initiate a phase IIa study in diabetes-induced retinopathy shortly, with potential for top-line data before year-end. Meanwhile, business development efforts continue.

Länk till analysen i sin helhet: https://www.redeye.se/research/1119256/annexin-q2-positioned-to-advance-dr-study-and-bd-efforts?utm_source=finwire&utm_medium=RSS